Drug intelligence / Profile preview

Wushen oral liquid

Development stage: Preclinical
Lead developer: Shuguang Hospital
Administration: Oral

Overview

Wushen oral liquid is a Traditional Chinese Medicine (TCM) product administered orally. It is being investigated in clinical trials for the treatment of Ventricular Precontraction after Percutaneous Coronary Intervention (PCI) for myocardial infarction, specifically in patients with a qi-yin deficiency type. Its therapeutic action is believed to stem from its traditional Chinese medicinal properties aimed at addressing this specific deficiency and improving cardiac function.

Brand names: Wushen Oral Liquid
Other names: 五参口服液

Beyond the preview

Go deeper on Wushen oral liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wushen oral liquid.

Explore the full profile